ZyVersa Therapeutics, Inc. (ZVSA) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Weston, FL, 미국. 현재 CEO는 Stephen C. Glover.
ZVSA 을(를) 보유 IPO 날짜 2022-02-11, 7 명의 정규직 직원, 에 상장 Other OTC, 시가총액 $1.55M.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
